Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 693-705

  Vilgelm, Anna E ^a,c   Washington, Mary K ^a   Wei, Jinxiong ^a   Chen, Heidi ^a   Prassolov, Vladimir S ^c   Zaika, Alexander I ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; LUCIFERASE; PROTEIN P53; PROTEIN P63; PROTEIN P73; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL STRESS; COLON CANCER; CONTROLLED STUDY; DNA BINDING; DRUG BINDING; DRUG INHIBITION; DRUG RESPONSE; ESOPHAGUS CANCER; GASTROINTESTINAL TUMOR; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TREATMENT RESPONSE; VIRUS INFECTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DNA-BINDING PROTEINS; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MULTIGENE FAMILY; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN ISOFORMS; STRESS, PHYSIOLOGICAL; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77949737597     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0912     Document Type: Article

References (40)

1. Waters JS, Ross PJ, Popescu RA, CunninghamD. New approaches to the treatment of gastro-intestinal cancer. Digestion 1997;6:508-19.
2. American Cancer Society. Colorectal cancer facts & figures special edition 2005. Atlanta: American Cancer Society; 2005.
3. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat 2006;1:14-20.
4. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;3:434-44.
5. Zaika AI, El-Rifai W. The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ 2006;6:935-40.
6. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003; 12:663-70.
7. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 2008;4-5: 152-63.
8. Hong SM, Cho H, Moskaluk CA, Yu E, Zaika AI. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol 2007;3:167-75.
9. Ventura A, Meissner A, Dillon CP, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 2004; 28:10380-5.
10. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008;19:5951-64.
11. Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001;14:11310-6.
12. Vilgelm A, Wei JX, Piazuelo MB, et al. ΔNp73α regulates MDR1 expression by inhibiting p53 function. Oncogene 2008;15:2170-6.
13. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 1992; 12:5581-92.
14. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 2004;18:6390-3.
15. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999;13:3257-63.
16. Wei J, O'Brien D, Vilgelm A, et al. Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology 2008;5:1412-23.
17. Zaika AI, Slade N, Erster SH, et al. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;6:765-80.
18. Liu Y, Asch H, Kulesz-Martin MF. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 2001;14:5402-6.
19. Tomkova K, El-Rifai W, Vilgelm A, Kelly MC, Wang TC, Zaika AI. The gastrin gene promoter is regulated by p73 isoforms in tumor cells. Oncogene 2006;44:6032-6.
20. Hara T, Kijima H, Yamamoto S, et al. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med 2004;2: 169-73.
21. Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009;10:3964-9.
22. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000;6804:645-8.
23. Gressner O, Schilling T, Lorenz K, et al. TAp63α induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005;13:2458-71.
24. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG, Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003;4:403-10.
25. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;2:1438-49.
26. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001;5: 1874-87.
27. Strano S, Fontemaggi G, Costanzo A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002;21:18817-26.
28. Lin KW, Nam SY, Toh WH, Dulloo I, Sabapathy K. Multiple stress signals induce p73β accumulation. Neoplasia 2004;5:546-57.
29. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient ΔTAp73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002;16:14177-85.
30. Liu G, Nozell S, Xiao H, Chen X. ΔNp73β is active in transactivation and growth suppression. Mol Cell Biol 2004;2:487-501.
31. Muller M, Schilling T, Sayan AE, et al. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
32. De Laurenzi V, Costanzo A, Barcaroli D, et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J Exp Med 1998;9:1763-8.
33. Scaruffi P, Casciano I, Masiero L, Basso G, Romani M, Tonini GP. Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL differentiation. Leukemia 2000;3:518-9.
34. Ueda Y, Hijikata M, Takagi S, Chiba T, Shimotohno K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 1999;35:4993-8.
35. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 6880:560-4.
36. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997; 1:78-82.
37. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999;39:27474-80.
38. Vincenzi B, Cesa AL, Santini D, et al. Predictive factors for response to chemotherapy in colorectal cancer patients. Crit Rev Oncol Hematol 2004;1:45-60.
39. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist Updat 2003;6:313-22.
40. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001;5:1839-42.